ArticleInternational journal of experimental pathology2001
Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro.
Article in International journal of experimental pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Preparation and Characterization of Collagen-Hyaluronic Acid (Col-HA) Matrices: In Vitro Mimics of the Tumor Microenvironment.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Interactions between Nitric Oxide and Hyaluronan Implicate the Migration of Breast Cancer Cells.Biomacromolecules · 2022Article
- Natural Presentation of Glycosaminoglycans in Synthetic Matrices for 3D Angiogenesis Models.Frontiers in cell and developmental biology · 2021Article
- A Step Forward in Breast Cancer Research: From a Natural-Like Experimental Model to a Preliminary Photothermal Approach.International journal of molecular sciences · 2020Article
- Article
- Molecular size-dependent specificity of hyaluronan on functional properties, morphology and matrix composition of mammary cancer cells.Matrix biology plus · 2019Article
- Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery.Marine drugs · 2019Article
- Nanotechnology and Glycosaminoglycans: Paving the Way Forward for Ovarian Cancer Intervention.International journal of molecular sciences · 2018Review
- Hyaluronic acid in digestive cancers.Journal of cancer research and clinical oncology · 2017Review
- Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells.Oncotarget · 2016Article
- A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?Omics : a journal of integrative biology · 2012Article
- Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion.The Journal of biological chemistry · 2011Article
- Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.AAPS PharmSciTech · 2009Article
- In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver.The American journal of pathology · 2007Article
- Directional sensing of a phorbol ester gradient requires CD44 and is regulated by CD44 phosphorylation.Oncogene · 2006Article
- Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells.Oncogene · 2006Article
- Nucleolin: acharan sulfate-binding protein on the surface of cancer cells.Glycobiology · 2005Article
- Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias - assessment of clinical outcome, post induction, end of treatment and minimal residual disease.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyaluronan (HA) is a high molecular weight glycosaminoglycan present mostly in the extracellular matrix (ECM). HA binds to specific receptors such as CD44. Its production is increased at the tumour-stroma interface, including those in breast cancer tumours. It has been suggested that it facilitates invasion of tumour cells into the ECM by a hydrodynamic effect, or by altering tumour cell behaviour. Using in vitro tests we studied the effect of immobilized (iHA) and soluble (sHA) HA on the invasive properties of four human breast cancer cell lines with different levels of CD44 expression. Our results show that iHA acts as an adhesive, haptotactic, and motility stimulating factor for the CD44 positive Hs578T cells and induces the expression of membrane CD44. sHA also changes the motility properties of the Hs578T and MDA-231 cells and increases their CD44 expression. sHA or iHA have no measurable effect on the adhesion, motility or CD44 expression of the ZR-75-1 and MCF-7 breast cancer cells. Our results establish that in high CD44 expressing breast cancer cells HA modulates tumour cell adhesion and motility and also increases the expression of its own receptor, CD44.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.